Tirzepatide is a dual-receptor agonist analog that targets both GIP and GLP-1 pathways
Clin Ther 29(1):139153 Buse JB, Rosenstock J, Sesti G, Schmidt WE, Montanya E, Brett JH et al (2009) Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)
Weight loss drugs are approved for use in adults with a BMI of 30 or greater, or a BMI of 27 or higher with weight-related health problems like high blood pressure or type 2 diabetes
and Sean Dyson, advances in biomarker science, patient stratification, digital and imaging tools, and delivery technologies that address the blood brain barrier are supporting growth across the field
Mounjaro (tirzepatide) currently offers the highest results with 22.5% average body weight loss at 72 weeks as per clinical trials